A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy, did not achieve its primary endpoint, according to findings published in Nature Medicine. A News and Views piece on the trial was published in the same journal issue.
$3.2 million per dose Elevidys fails to meet primary endpoint in phase 3 trial
